Drugs that contain Tolvaptan
1. Jynarque patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972882 | OTSUKA | Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists |
Dec, 2018
(5 years ago) | |
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2020
(3 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-178) | Apr 23, 2025 |
| New Indication(I-779) | Apr 23, 2021 |
Market Authorisation Date: 23 April, 2018
Treatment: Treatment of autosomal dominant polycystic kidney disease
Dosage: TABLET;ORAL
How can I launch a generic of JYNARQUE before it's drug patent expiration?
More Information on Dosage
JYNARQUE family patents
2. Samsca patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5258510 | OTSUKA | Benzoheterocyclic compounds |
Nov, 2013
(10 years ago) | |
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2020
(3 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Treatment: Method of treating hyponatremia
Dosage: TABLET;ORAL
How can I launch a generic of SAMSCA before it's drug patent expiration?
More Information on Dosage
SAMSCA family patents